Definitive irradiation of T1-T4N0 larynx cancer.
The use of definitive irradiation in T1-T4N0 larynx cancer was reviewed in 236 patients at Rush-Presbyterian-St. Luke's Medical Center in Chicago. Recurrence-free survival for all stages was 86% at five years. Ultimate recurrence-free survival, including successful surgical salvage, was 91% at five years. The data described herein and the literature reviewed support the recommendation for definitive radiation therapy for T1 and T2N0 larynx cancer of any site. T3 lesions may also be reasonably treated with radiation therapy initially, reserving surgery for salvage. However, more data are needed to accurately identify the T3 larynx cancer patients most suited for radiation therapy.
D000328:Adult; D000368:Aged; D002278:Carcinoma in Situ / Q000532:radiotherapy* / Q000601:surgery; D002294:Carcinoma, Squamous Cell / Q000532:radiotherapy* / Q000601:surgery; D005260:Female; D005931:Glottis / Q000473:pathology; D006801:Humans; D007822:Laryngeal Neoplasms / Q000473:pathology / Q000532:radiotherapy* / Q000601:surgery; D007825:Laryngectomy; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000601:surgery; D009367:Neoplasm Staging; D011379:Prognosis; D013997:Time Factors; D014827:Vocal Cords / Q000473:pathology